ArticleHepatobiliary surgery and nutrition2017
Hepatocellular carcinoma with macrovascular invasion treated with yttrium-90 radioembolization prior to transplantation.
Article in Hepatobiliary surgery and nutrition, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Portal vein tumor thrombosis in hepatocellular carcinoma patients: Is it the end?Liver research (Beijing, China) · 2024Review
- Expanding Indications for Liver Transplantation in the Treatment of Hepatocellular Carcinoma.Current oncology (Toronto, Ont.) · 2024Review
- Impact of neoadjuvant multimodal therapy in the setting of locally advanced hepatocellular carcinoma.World journal of gastroenterology · 2024Article
- Selective internal radiation therapy for unresectable HCC: The SIRT downstaging study.Hepatology communications · 2024Observational
- Yttrium-90 Radioembolization: Current Indications and Outcomes.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2023Review
- Predictors of mortality within the first year post-hepatectomy for hepatocellular carcinoma.Journal of the Egyptian National Cancer Institute · 2022Article
- Neoadjuvant treatment strategies for hepatocellular carcinoma.World journal of gastrointestinal surgery · 2021Review
- Review
- Liver transplantation for hepatocellular carcinoma with portal vein tumor thrombosis.Journal of liver cancer · 2021Review
- The Progress in the Treatment of Hepatocellular Carcinoma With Portal Vein Tumor Thrombus.Frontiers in oncology · 2021Review
- Comparison of Liver Transplantation and Liver Resection for Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombus Type I and Type II.Yonsei medical journal · 2021Article
- Treatment of hepatocellular carcinoma in patients with portal vein tumor thrombosis: Beyond the known frontiers.World journal of gastroenterology · 2019Review
- Current State of Liver-Directed Therapies and Combinatory Approaches with Systemic Therapy in Hepatocellular Carcinoma (HCC).Cancers · 2019Review
- Paraneoplastic leukemoid reaction in a patient with sarcomatoid hepatocellular carcinoma: A case report.World journal of clinical cases · 2019Article
- Extremes of Liver Transplantation for Hepatocellular Carcinoma.Journal of clinical medicine · 2019Article
- The prognosis of bulky hepatocellular carcinoma with nonmajor branch portal vein tumor thrombosis.Medicine · 2019Article
- How to identify better candidate to radioembolization in case of hepatocellular carcinoma and portal vein tumoral thrombosis.Hepatobiliary surgery and nutrition · 2019Article
- Treatment strategies for locally advanced hepatocellular carcinoma.Translational gastroenterology and hepatology · 2019Review
- Radioembolization in the setting of liver transplantation: great expectations or hard times?Hepatobiliary surgery and nutrition · 2018Article
- Liver transplant for patients outside Milan criteria.Translational gastroenterology and hepatology · 2018Article
Corrections and comments
- Commented on by
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundYttrium-90 microspheres radioembolization (Y90-RE) has shown to be an effective and safe treatment of primary liver tumors. According to the staging system of the Barcelona Clinic Liver Cancer (BCLC), patients with macrovascular invasion are staged as BCLC-C. This paper comprises a presentation of the results following application of the procedure.
methodsFrom January 2002 to December 2015, 367 patients were transplanted at the San Camillo Hospital Center. One hundred and forty-three patients were transplanted for hepatocellular carcinoma (HCC) and in 22 cases patients were treated with Y90-RE before liver transplantation (LT), of them 4 with macrovascular invasion were included in this study.
resultsThe four patients had a complete response for the thrombosis, and were included in the waiting list within the Milan criteria. Means interval time between Y90-RE and LT was 15.86 months. No patient death was observed at Y90-RE procedure or at LT. We obtain a free-survival of 39.1 (range, 6-76) months. In all four cases the complete thrombosis regression was observed.
conclusionsWe reported a short series of patients transplanted after Y90-RE in patients with BCLC stage C. In our experience we achieved acceptable overall and disease-free survival. Eventually, Y90-RE seems to have a place in the downstaging strategy for LT candidates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.